BioPharma Clinical Trials
Zuellig Pharma Acquires Hangzhou Facility to Strengthen Clinical Trial Supply in China
The acquisition of our newly licensed Hangzhou facility establishes robust local sourcing capabilities to accelerate and support clinical trials across Chi...
November 05, 2026 | News
Minghui Signs Japan Licensing Deal With ASKA Worth Up to $440 Million for Thyroid Eye Disease Therapy
Minghui Pharmaceutical ("Minghui") and ASKA Pharmaceutical Co., Ltd. ("ASKA") announced that they have entered into an exclusive license agreement fo...
November 05, 2026 | News
Brise Pharmaceuticals and AbbVie Advance Migraine Drug Collaboration Worth Up to $757 Million
Brise Pharmaceuticals Co., Ltd. provided an update on its exclusive license agreement with AbbVie (NYSE: ABBV), which the companies entered in 2024. Under ...
November 04, 2026 | News
Pierre Fabre Launches BRAFTOVI–MEKTOVI Combination for BRAF-Mutant Lung Cancer in Singapore
New targeted treatment option now available in for adult patients with BRAFV600E mutant advanced non-small cell lung cancer (NSCLC) Launch follows Europ...
November 04, 2026 | News
InventisBio’s Nomelcitinib Achieves Over 70% PASI 90 Response in Phase III Psoriasis Trial
InventisBio Co., Ltd. announced that its JH2 selective TYK2 inhibitor nomelcitinib (D-2570) has met both the primary endpoint and the key s...
November 04, 2026 | News
China's 2026 Reimbursement Lists: 10 Drugs That Will Show Where Beijing Is Paying, and the Commercial List's Second Year
Where things stand. As of 2 November 2026, the National Healthcare Security Administration (NHSA) has not published the 2026 National Reimbursement Drug Li...
November 03, 2026 | Regulatory
InventisBio’s Nomelcitinib Achieves Both Primary and Key Secondary Endpoints in Phase III Psoriasis Trial
InventisBio Co., Ltd. announced that its JH2 selective TYK2 inhibitor nomelcitinib (D-2570) has met both the primary endpoint and the key seconda...
November 03, 2026 | News
Lynk Pharmaceuticals Expands Simcere Partnership to Commercialise Zemprocitinib for Atopic Dermatitis in Greater China
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), announced that it has expanded its commercialization collaboration with Simcere Pharmaceutical Gro...
November 03, 2026 | News
Zhimeng Biopharma Completes Enrolment of 255 Patients in Pivotal ALS Phase II/III Trial in China
Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma") announced that its independently developed next-generation potassium channel opener, CB03-154,...
November 03, 2026 | News
Nuance Pharma Doses First Patient in China Phase III Trial of Actair for House Dust Mite Allergy
Nuance Pharma announced that the first patient has been dosed in the REACH Phase III clinical trial evaluating STG320 (Actair®) for the treatment of ho...
November 03, 2026 | News
Alkermes Advances Orexin-Based Depression Treatment into Phase II Clinical Trial
Alkermes plc announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants ...
November 02, 2026 | News
Pretzel Therapeutics Secures UK Approval to Advance PX578 into Phase II Trial for Rare Mitochondrial Disease
Regulatory milestone follows U.S. FDA clearance of Investigational New Drug application in August 2026 Initiation of Phase 2 Trial in POLG-PMD (POLG Dis...
November 02, 2026 | News
Immunome’s Varegacestat Moves into European Regulatory Review Following Positive Phase III Results
The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically significant improvements ac...
November 02, 2026 | News
Parse Biosciences and Nomic Bio Launch 100-Million-Cell Immune Dataset to Advance AI Drug Discovery
Parse Biosciences, a leading provider of scalable and publicly available single-cell sequencing technology, a subsidiary of QIAGEN, andNomic Bio, a leader ...
November 02, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
